Sphingomyelin and ceramide are physiological ligands for human LMIR3/CD300f, inhibiting FcεRI-mediated mast cell activation

J Allergy Clin Immunol. 2014 Jan;133(1):270-3.e1-7. doi: 10.1016/j.jaci.2013.08.008. Epub 2013 Sep 12.

¹ Division of Cellular Therapy, The Institute of Medical Science, University of Tokyo, Tokyo, Japan; Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan.
² Division of Cellular Therapy, The Institute of Medical Science, University of Tokyo, Tokyo, Japan.
³ Division of Cellular Therapy, The Institute of Medical Science, University of Tokyo, Tokyo, Japan; Division of Stem Cell Signaling, The Institute of Medical Science, University of Tokyo, Tokyo, Japan.
⁴ Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan; Atopy Research Center, Juntendo University School of Medicine, Tokyo, Japan.
⁵ Division of Cellular Therapy, The Institute of Medical Science, University of Tokyo, Tokyo, Japan; Division of Stem Cell Signaling, The Institute of Medical Science, University of Tokyo, Tokyo, Japan. Electronic address: kitamura@ims.u-tokyo.ac.jp.
⁶ Division of Cellular Therapy, The Institute of Medical Science, University of Tokyo, Tokyo, Japan. Electronic address: kitaura-tky@umin.ac.jp.

No abstract available

Publication types